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Abstract
Introduction:Myofascial pain syndrome (MPS) is a common chronic pain disorder that lacks effective diagnostic criteria. To better
understand neurophysiological changes in chronic pain, several trials exploring corticospinal excitability in different populations of
patients with chronic pain have been performed.
Objectives: In this systematic review, we aimed to investigate the current literature onMPS and intracortical disinhibition, by means
of increased intracortical facilitation and decreased intracortical inhibition (ICI).
Methods: We performed a search on PubMed to identify clinical trials on MPS and transcranial magnetic stimulation
measurements. We then applied the Harford Hill criteria to the identified studies to assess the possible causal relationship between
intracortical disinhibition measurements and MPS. Finally, we compared our findings on MPS with other chronic pain conditions.
Results: Four studies assessing corticospinal excitability in patients with MPSwere found. Although the amount of trials available is
limited, all the reported studies indicated an increased intracortical disinhibition in patients with MPS. Importantly, these
measurements were also correlated with psychological factors, such as pain catastrophism, or anxiety. However, based on the
Harford Hill criteria, we could not assert a strong causal relationship between these markers and MPS. Although intracortical
disinhibition has been consistently found in patients having MPS, this lack of cortical inhibition was not only observed in this specific
chronic pain syndrome but also in fibromyalgia and neuropathic pain conditions.
Conclusion: Intracortical disinhibition seems to be amarker that has been consistently observed inMPS. Future prospective cohort
studies could provide new insights in the development of neoplastic andmaladaptive changes occurring in chronic pain syndromes
and help the development of new therapeutic options.
Keywords:Myofascial pain syndrome, Disinhibition, Intracortical inhibition, Intracortical facilitation, Cortical excitability, Pain,
Motor cortex
1. Introduction
Myofascial pain syndromes (MPSs) are a group of painful
conditions that affect muscles and connective tissues.26 These
musculoskeletal disorders involve the sensory, motor, and
autonomic systems and are characterized by skeletal muscle
fibers nodules, which are called myofascial trigger points
(MTrPs).22 These MTrPs are characterized by focal muscle
hyperirritability to a sustained stimulus, and involve, among others,
the integration of cellular signaling, neuromuscular inputs,
excitation-contraction coupling, and the hemodynamic system.26
These sustained nociceptive stimuli induce the apoptosis of
inhibitory neurons at the segmental levels affectedby theperipheral
noxious input, and such an action can sensitize dorsal horn
neurons leading to allodynia, hyperalgesia, temporal summation of
pain, and expanded pain patterns.4 Myofascial trigger points
represent a major clinical sign of MPS that differentiate this
syndrome fromother chronic pain syndromes such as fibromyalgia
and neuropathic pain syndromes.20,21 Traumatic events,muscular
overloads, psychological stress, and systemic pathology may lead
to the development of MTrPs. These MTrPs can either resolve
spontaneously or become chronic, at which point, patients may
develop MPS. However, the exact pathophysiology of MPS
development is still not entirely understood. As with other chronic
pain syndromes, it is particularly difficult to determine the
underlying mechanisms of MPS given that pain involves the
nervous system at various levels: cortical areas, the limbic system,
the thalamus, the spinal–bulbospinal loop, and the spinal reticular
tract; all constitute the so-called “pain matrix”.64
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In chronic pain syndrome, cortical alterations are frequently
found, with the motor cortex as the most commonly reported
cortical area. Corticospinal excitability, measured by transcranial
magnetic stimulation (TMS), represents a valuable tool to better
characterize neurophysiological mechanisms of chronic pain.34 A
valuable biomarker in chronic pain is intracortical disinhibition, as
measured by intracortical inhibition and intracortical facilitation
(ICI and ICF, respectively; for a review Ref. 23). A decrease in ICI
could indicate lack of inhibition, or disinhibition, and an increase in
ICF. This disinhibition is thought to be a determining factor in
chronic pain syndromes,23 leading to a hyperexcitability of the
motor cortex. Modifications of these cortical excitability param-
etersmay also be influenced by the chronicity of the condition, the
severity of symptoms, medication, and additional factors such as
psychiatric disorders. Other neurophysiological methods, such
as functional magnetic resonance imaging (fMRI) and event-
related potential, also demonstrated these cortical changes in
chronic pain (for recent reviews Ref. 42, 49). For instance,
patients with fibromyalgia present a different activation pattern as
compared to healthy subjects during both nonnociceptive
sensory and painful stimulations and show an excess of cortical
activity.5,12,50
As intracortical disinhibition is a reliable marker of motor
cortical excitability dysfunction as indexed by TMS (specifically ICI
and ICF alteration), the purpose of this systematic review was to
first analyze these findings, and second, to explore and discuss
their meanings in the context of mechanisms of pain in MPS.
Therefore, we (1) defined intracortical disinhibition as indexed by
TMS and its relationship with pain; (2) reviewed the findings of
clinical trials assessing corticospinal excitability in MPS; (3)
evaluated the causal relationship between findings of intracortical
disinhibition and MPS based on Bradford Hill causality criteria;
and (4) discussed if these measurements of intracortical
disinhibition are specific for MPS.
2. Primary motor cortex disinhibition as indexed by
transcranial magnetic stimulation and its
relationship with pain
2.1. Parameters of motor cortex excitability: understanding
their meaning
Motor-evoked potential (MEP) is a muscular response recorded
using electromyography, when an electrical or magnetic stimu-
lation is evoked, for instance using TMS, over the motor cortex.
This measurement is used to describe themotor nerve excitability
and integrity and reflects the global corticospinal excitability.
Resting motor threshold (MT), which is another measure of global
corticospinal excitability, is defined as theminimum TMS intensity
sufficient to produce a predefined MEP in the contralateral
targeted muscle in at least 50% of trials with an amplitude of
50 mV.52
The cortical silent period (CSP) refers to the refractory period
occurring after the action potential. To record it, a suprathreshold
stimulation is applied over the contralateral motor cortex during
voluntary contraction of a target muscle, resulting in a period of
electromyographic silence for up to several hundred millisec-
onds.25 A decrease in CSP latency can be interpreted as lack of
inhibition or disinhibition. Pharmacological interventions suggest
that CSP is, in part, related to the activity of the gamma-
aminobutyric acid (GABA)ergic neurotransmitter system. Several
trials reported a prolongation of the CSP latency when subjects
were given baclofen (GABAB agonist).
59,61 Short interval intra-
cortical inhibition (SICI) is another parameter of cortical
excitability. It is measured by paired-pulse TMS, during which
a pulse is delivered after 1 to 6 milliseconds after a subthreshold
stimulation.72 The amplitude of the MEP of the second pulse is
usually found to be reduced.
The physiologicalmechanism for SICI is thought to be aGABAA
receptor–mediated inhibition of motor cortex output cells.15,71
Indeed, it has been shown that its duration is enhanced by
benzodiazepines, which are allosteric positive modulators of the
GABAA receptor.
15,71 The duration of SICI is approximately 20
milliseconds, which is similar to inhibitory postsynaptic potential.2
Because SICI is modulated by drugs that enhance the GABAA
inhibitory system,27,70 the SICI duration is thought to be linked to
inhibitory postsynaptic potential from the GABAA receptor
stimulation.37
Regarding intracortical ICF, similar paired-pulse TMS is used,
with a pulse delivered 6 to 20 milliseconds after a subthreshold
stimulation.72 In this case, an increase in the pulse amplitude is
usually found, as compared to a single test pulse. Intracortical
facilitation originates from excitatory postsynaptic potentials
mainly mediated by glutaminergic N-methyl-D-aspartate (NMDA)
receptors.43 However, the physiological and mechanisms for ICF
are still not entirely understood. It has also been hypothesized that
ICF is not only mediated by excitatory mechanisms but by
a balance between inhibition and excitation.51
2.2. Relationship between M1 and pain
Pain is a complex phenomenon involving multiple nervous
system functions, including sensory, affective, cognitive, and
motor components. The specific interactions between pain and
the motor cortex are not yet fully understood. However, that
brain regions involved in motor function, such as the primary
motor cortex, supplementary motor area, the anterior cingulate
cortex, the lenticular and caudate nuclei, and the cerebellum,
have expressed metabolic modifications after a painful
stimulus.48
Although the primary motor cortex (M1) is not part of the pain
matrix, it is considered to play a key role in modulation of pain in
different chronic pain syndromes. M1 has wide connections to
some of the sensory relay nuclei in the thalamus and to efferent
and afferent fibers in the spinal cord responsible for transmission
of painful stimuli and modulation of motor response to noxious
stimuli. Many trials on patients with chronic pain have identified
a maladaptive plasticity process in this specific cortical area.39,54
In addition, studies on both animal models and humans have
shown thatmodulation ofM1 activity induces important analgesic
effects. For instance, simply observing a moving hand has been
shown to increase the pain threshold, whereas observing a still
hand decreases the threshold.67 This allows us to hypothesize
that M1 can act as amodulator of pain processing, and therefore,
influencing its baseline activity could lead to changes in pain
perception in chronic pain syndromes. Different types of
interventions such as noninvasive brain stimulation (NIBS)
techniques can target this cortical area, to modulate its activity
in order to modify its output responses regarding pain perception
(for a review Ref. 32).
2.3. Relationship between intracortical disinhibition and pain
The most common hypothesis of chronic pain syndromes
mechanisms, such as fibromyalgia, is based on the central
sensitization theory and is related to a dysfunction in the extensive
neural circuit responsible for processing pain. One such
hypothesis, central sensitization, is a proposed physiological
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phenomenon in which central nervous system neurons become
hyperexcitable, or less inhibited, because of modifications of
peripheral and central nervous system as a consequence of
chronic noxious stimuli,44 resulting in hypersensitivity of both
noxious and nonnoxious stimuli.68
The phenomenon of disinhibition, by means of increase in ICF
and/or decrease in ICI, is thought to be the consequence of
a dysregulation of GABA-dependent inhibition and NMDA-
dependent excitatory circuits.70,72 These changes in cortical
plasticity could be explained as a compensatory mechanism to
downregulate increased excitability in the pain neural networks
such as thalamic structure, as previously hypothesized.6 Al-
though cortical disinhibition can be interpreted as a decreased ICI
and/or an increased ICF, it should be noted that various
differences exist between these 2 parameters in terms of
neurobiological bases, neurotransmitters involved, or thresholds
to obtain. These should be taken into account when analyzing
and interpreting the results of a trial.
When the intensity of a painful stimulus increases, the pain-
inhibitory system can be disrupted as a summation effect. This
cortical disinhibition phenomenon can amplify the intensity of
pain signals from the peripheral nervous system to the neural
pain matrix and, thus, can lead to increased pain sensation.3 In
fact, lack of motor activity can enhance this mechanism by
a feedback loop. This finding has been observed in MPS, and in
conditions such as fibromyalgia and migraine, whereas it has
not been identified in nociceptive pain such as osteoarthritis.8
This gives us a better understanding on how to develop
treatments for neuropathic chronic pain, by increasing ICI or
decreasing ICF. For instance, NIBS technique, particularly
repetitive TMS (rTMS), has been shown to reduce pain and
disinhibition in patients with neuropathic pain,33 whereas for
patients having nonneuropathic pain who do not express
cortical disinhibition, rTMS did not induce the same analgesic
effect.57
3. Human studies evaluating corticospinal
excitability in myofascial pain syndrome
To analyze intracortical disinhibition in MPS, we performed
a search on PubMed using the following terms: “myofascial pain
syndrome” and “TMS” or “Transcranial Magnetic Stimulation” or
“cortical excitability”. We also looked at the reference list of the
articles we retrieved to check if there were any additional articles.
We also contacted experts in the field of MPS and TMS. Finally,
we looked at neuromodulation meetings proceeding to check if
there was any unpublished manuscript on MPS and cortical
excitability.
We included articles involving patients with MPS and assess-
ing cortical excitability. We excluded articles that were not
focusing on MPS or articles that did not report cortical excitability
measurements. Reviews and articles not written in English were
also excluded.
Of the 24 articles researched, 4 were found to investigate
cortical excitability in MPS (Fig. 1).
3.1. Cortical excitability of the motor cortex in myofascial
pain syndrome and its relationship with pain catastrophizing
In a study conducted by Volz et al (2013), we aimed to explore the
relationship between a neurophysiological marker of cortical
excitability, as assessed by TMS, and catastrophizing, as
assessed by the Brazilian Portuguese Pain Catastrophizing Scale
(B-PCS), in patients with chronic MPS. We included 24 patients
having MPS (all women, age 48 6 13 years).66 In this study, MT,
ICI, and ICF measurements were collected to assess cortical
excitability and compared the results with patients’ level of pain
catastrophizing and pain as measured by pain pressure
threshold. Intracortical facilitation was found to be significantly
associated with pain catastrophizing, whereas SICI was associ-
atedwith pain pressure threshold scores, with positive correlation
between the 2 factors (decrease in SICI was related to lower pain
threshold). In addition, ICF was positively correlated to the
magnitude of pain (severity, interference with daily activity, and
emotional burden, as measured by the Profile of Chronic Pain:
Screen for a Brazilian Population–B-PCS9,53). In conclusion, we
suggested that glutamatergic activity may be associated with
mechanisms underlying pain catastrophizing. These results are in
linewith previous findings on other chronic pain pathologies, such
as fibromyalgia, reporting impaired ICI.34,36
3.2. Relationship between anxiety and intracortical inhibition
and pain modulation in myofascial pain syndrome
In the second study by Vidor et al (2014), we aimed to investigate
how anxiety could influence cortical excitability, as quantified by
CSP, ICI, and ICF, and pain modulation, as measured by
conditioned pain modulation (CPM).65 Forty-seven patients with
MPS (47 women, age: 47 6 11.5 years) were included in this
study. We found that anxiety was positively correlated with ICF
and negatively correlated with CSP. In addition, we observed that
the interaction between pain and anxiety reduced the CPM
responses. This suggest that the function of the descending
modulatory system was reduced when there was increase
disinhibition, as already shown in other chronic pain condi-
tions.31,55 When assessing the correlation between B-PCP and
cortical excitably markers, a positive correlation with ICF was
found, whereas no correlations with ICI nor CSP were identified.
This study showed that the influence of anxiety on pain is linked to
central sensitization of nociceptive neurons, which contribute to
an aggravation of chronic pain symptoms.
3.3. Relationship between cortical excitability, descending
pain modulation system, and brain-derived neurotrophic
factor in myofascial pain syndrome
Our third article, from Botelho et al (2016), investigates the
relationship between neurophysiological, neurochemical, and
clinical outcomes in MPS.We studied the relationship between
descending pain modulation (ie, CPM), corticospinal excitabil-
ity, and brain-derived neurotrophic factor (BDNF) as a marker
of neuroplasticity, in MPS.3 In this cross-sectional study, we
investigated the relationship between cortical excitability and
BDNF levels in 33 women with chronic MPS who responded (n
5 10, age: 486 9 years) and did not respond (n5 23, age: 43
6 15 years) to CPM. Nonresponders had an increase in ICF
and higher BDNF levels as compared to responders. In
addition, nonresponders expressed greater disability related
to pain and a lower level of heat pain threshold. As in the
second study, no effect was observed on ICI between
responders and nonresponders, nor between pain assess-
ments (B-PCP) and this cortical parameter. The authors
suggested that the increased central sensitization related to
chronic pain leads to a loss of descending pain inhibition, or
disinhibition, that would cause compensatory mechanisms
shown by an increase in cortical excitability. They also
proposed that BDNF level could be a marker of central
sanitization, which is caused by enhanced membrane and
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synaptic activity, combined with a decrease in inhibition in the
somatosensory system.30
3.4. Comparison of cortical disinhibition patterns in
myofascial pain syndrome and other chronic
pain syndromes
In this fourth study, by Caumo et al (2016), we aimed to better
understand the mechanisms associated with the central sensi-
tization, as it is a critical component of chronic pain syndromes. In
this cross-sectional study, we included 114 women, aged 19–65
years old, with chronic pain syndromes. Nineteen were di-
agnosed with fibromyalgia, 54 with MPS, and 27 with osteoar-
thritis, as well as 14 healthy subjects. We assessed serum BDNF
level, motor cortex excitability parameters, and change on pain
sensation during CPM task.8 Patients with MPS presented higher
SICF and lower SICI and CSP, as compared to healthy controls.
Except for MEP, which is more elevated in MPS subjects, the
other parameters of intracortical disinhibition were similar to those
observed in patients with fibromyalgia. Patients with osteoarthritis
expressed different cortical excitability patterns when compared
with the other 2 conditions, results closer to what was observed in
healthy controls. We also identified that BDNF levels were
negatively correlated with SICI and the level of pain during
CPM. These findings suggest that patients with MPS and
fibromyalgia have a larger disinhibition pattern in the motor cortex
and the descending pain-inhibitory system than that of patients
with osteoarthritis. This means that the disinhibition of the motor
cortex and the dysfunction in the descending pain regulatory
system is more severe in patients without tissue injury (MPS and
fibromyalgia) than in patients with structural lesions (osteoarthri-
tis). Based on these results, we proposed that increased BDNF
levels might also be involved in these pathological processes
(disinhibition of motor cortex and dysfunction of descending
inhibitory pain modulation system), but independently from the
physiopathological mechanisms of musculoskeletal chronic pain
syndromes.
The results of these 4 studies confirmed that disinhibition of the
motor cortex, by means of an increase in ICF or a decrease in ICI,
is a central marker of MPS. These markers were reproducibly
altered in these 4 trials, which make them reliable biomarkers of
this pathology. In addition, factors such as anxiety or pain
catastrophizing and enhanced pain symptomswere correlated to
a greater dysregulation of cortical inhibition.65,66 Increased
cortical disinhibition was also associated with increased BDNF
levels, which could be linked to synaptic plasticity, inducing
a higher nociceptive transmission.3 Finally, cortical inhibition and
facilitation in different populations of patients with chronic pain,
both without tissue injury (MPS and fibromyalgia), and with
structural lesions (osteoarthritis), different patterns were identi-
fied.8 Patients with structural lesions did not present this lack of
cortical inhibition, whereas patients with fibromyalgia demon-
strated the same dysregulation than patients with MPS, except
for MEP, which represents the excitability of corticospinal
tracts.47 It has been hypothesized that MPS and fibromyalgia
are part of the same syndrome but at different time points,
Figure 1. PRISMA flow chart describing identification and selection of studies for this systematic review.
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explaining the highly similar cortical excitability pattern between
these 2 conditions.17 It should be noted that all 4 studies included
female participants only. Therefore, we cannot generalize these
findings to the entire population of patients with MPS, although
women tend to be more often affected than men.19 The meaning
of these biomarkers of intracortical disinhibition, and the
similarities and differences between several chronic pain syn-
dromes, will be further discussed in the next sections. In addition,
it should be emphasized that all these studies were performed by
our group, and therefore there is a lack of parallel work from other
research investigators that could confirm our findings.
4. Is there a causal relationship between
measurements of intracortical disinhibition and
myofascial pain syndrome?
Here we aimed to evaluate the causal relationship between ICI
and MPS using a qualitative approach to better characterize the
validity of ICI as a biomarker for MPS. However, it needs to be
acknowledged that it is possible that a causal relationship
between these 2 variables does not exist, although ICI may still
be useful as a marker of treatment, for example. To determine
whether a causal relationship between a decrease in ICI and level
of pain in MPS exists, we applied the Bradford Hill criteria24 to our
findings. Bradford Hill defined 9 criteria (strength, consistency,
specificity, temporally, biological gradient, plausibility, coherence,
experiment, and analogy). As only 4 trials assessed this relation-
ship (see previous section), we could not translate their findings to
all the criteria listed above.
4.1. Strength
Although the effect size of the correlations was not reported in all
studies, we can evaluate the strength with the R2 of the models
assessing the correlation between ICI or ICF and pain measure-
ments or the Pearson correlation coefficient. In the first study,
the R2 for the ICI and pressure pain threshold model was 0.19
(pain threshold explains 19% of the variance of the ICI).66 Only
a trend to significance was found for ICF. The second study
showed an effect size of 0.19 in a model assessing the
correlation between ICF and pain measurements.65 A similar
relationship between ICF and pain measurements (Pearson
correlation coefficient r 5 0.45; P , 0.01) was identified in the
third trial, whereas no significant correlation was identified for ICI
nor CSP.3 For the last study, the authors demonstrated that
patients with MPS express a significant decrease in ICI and CSP
and increase in ICF, as compared to healthy controls.8 These
results demonstrate that intracortical markers of disinhibition
represent an important factor of pain control and modulation in
patients with MPS; however, to date, these studies show a mild
strength of this association.
4.2. Consistency
Two studies reported an association between pain measure-
ments and ICF, one between pain and ICI, and the fourth one
demonstrated that patients with MPS express decreased ICI and
increased ICF as compared to healthy controls. If we consider ICI
and ICF as markers of cortical disinhibition, all studies demon-
strated the association between either pain and intracortical
disinhibition or the lack of inhibition in patients with MPS,
compared to healthy controls. These reported results are
consistent and reproducible through the 4 trials investigating
intracortical disinhibition in patients with MPS.
4.3. Specificity
As observed in Caumo et al (2016),8 patients with fibromyalgia
and MPS share some similarities because both pathologies
expressed a reduction of ICI and an increase in ICF. In other
etiologies, such as chronic pain after limb amputation,10,58
patients with complex regional pain syndrome,35,56 or neuro-
pathic pain syndromes,57 there has also been reports of cortical
disinhibition. Therefore, the specificity can be considered low.
4.4. Plausibility
The disinhibition phenomenon occurring in MPS is in line with the
sensitization theory. Central sensitization involves a proliferation
of synaptic activity due to trophic factors to support maladaptive
plasticity that perpetuates the sensation of pain. Intracortical
disinhibition is the consequence of an imbalance between the
excitatory and inhibitory system, mediated by the reduction and
activation of GABA and NMDA, respectively.46 Consequently,
this lack of inhibition in ICI in patients with MPS explains the
observed increase in ICF and decrease in ICI, and with regards to
the primary motor cortex, is also understood to function as an
important pain modulator. Therefore, plausibility can be consid-
ered high.
4.5. Coherence
When looking at animal studies, only a few trials used a rat model
of MPS. One study investigated the role of GABAA receptor
expression in MPS and demonstrated the reduction of these
receptors in rats with MPS,29 which is in line with the theory of
disinhibition in humans, as evaluated by intracortical excitability
measurements.
4.6. Experiment
OneTMS trial investigated the effect of excitatory rTMSonpain relief
in patients with MPS.14 In this study, the authors showed that 10
sessions of rTMSdecreased pain and induced a reduction of ICF by
24%. However, no effect on SICI and CSP could be detected. This
experiment demonstrated that a reduction of pain could be linked to
a normalization of intracortical measurement and a reduction of
intracortical disinhibition. This relationship has been found in other
neuropathic pain syndromes. For instance, Lefaucheur et al (2006)
identified that a decrease in ICI was correlated with pain relief,
suggesting a restoration of defective intracortical inhibitory pro-
cesses.33,34 Thus,measurements of intracortical disinhibition seem
to be a reliable marker of chronic pain for some specific etiologies
(ie, absence of structural pathology).
4.7. Analogy
Other markers of neuronal activity such as electroencephalogram
or fMRI have been used to better understand the mechanisms of
various pain conditions. However, so far only one study used fMRI
to assess functional connectivity, white matter integrity using
diffusion tensor imaging, and fractional anisotropy in patients with
MPS.40 The authors found hypoconnectivity in the frontoparietal
attention network in patients with MPS as compared to healthy
controls. These findings demonstrate the abnormal cortical
activity in patients with MPS; however, they are not related to
an increase in cortical excitability or activity and do not emphasize
the mechanisms of cortical disinhibition in this population of
patients.
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As mentioned by Fedak et al, 2015, the causal relationship
between a condition and a factor can be very complex because
diseases are the results of the interaction and balance between
multiple factors.16 In our analysis, we did find some factors that
would support a causal role, such as coherence, plausibility, and
experiment. However, there are only a few studies to test for these
factors and criteria, such as strength, specificity, and consis-
tency, which are also affected by the low number of studies.
In the present scenario, therefore, there is some initial evidence
supporting the relationship between MPS and measurements of
intracortical disinhibition; nevertheless, the present evidence still
preliminarily supports a causal relationship between these 2
factors. Indeed, patients with other conditions seem to express
the same alterations in cortical excitability than patients with MPS
(see section 5), and these markers are influenced by parameters
other than pain, such as depression, anxiety, or pain catastroph-
izing. In addition, the 4 studies evaluating ICI and ICF in patients
with MPS did not show the exact same results. The investigator
and the clinician should then interpret this evidence as potentially
useful to better understand the mechanisms of MPS; however,
consideration should be given to the fact that this evidence is still
in its early stages.
5. Specificity of intracortical disinhibition in
myofascial pain syndrome
As discussed above, other chronic pain syndromes such as
fibromyalgia36 present the same cortical disinhibition pattern as
measured by a reduction of ICI and/or an increase in ICF.
Fibromyalgia seems to be the closest pathology to MPS and
intracortical excitability parameters present the same dysregula-
tion of cortical inhibition in the motor cortex.8,39 Interestingly,
rTMS-related pain reduction was correlated to modification of
ICI,38 as shown in patients with MPS.14 These 2 musculoskeletal
chronic pain syndromes shared pathophysiological similarities
that could explain the presence of intracortical disinhibition in
both syndromes.17,18,20
Although pathophysiological mechanisms of pain are widely
different fromMPS,modifications in cortical excitability have been
identified in patients with limb amputation. Schwenkreis et al
(2000) found a significant reduction of ICI coupled with an
enhancement of ICF in the affected side: the contralateral
hemisphere of the amputated limb.58 Note that even if the
relationship between pain and cortical disinhibition was not
directly investigated, all patients included in that study had an
average pain of 3.5 on the visual analog scale.
For chronic pain syndromes with structural lesions such as
osteoarthritis, this disinhibition phenomenon was not observed.
Indeed, patients with osteoarthritis seem to have the same
cortical excitability parameters as healthy controls, as previously
described in Caumo et al (2016).8 The authors suggested that this
difference between patients with MPS or fibromyalgia (scarcity of
tissue injury) and patients with osteoarthritis (structural lesion)
could be explained by distinct plastic changes in pain pathways.
Indeed, in osteoarthritis, pain arises by the activation of primary
nociceptive afference from the damaged tissue, whereas in other
neuropathic pain syndromes, pain occurs without this activation
of nociceptors.63 Therefore, a sustained activation of the
nociceptive system leads to an involvement of different brain
networks as compared to pain occurring in the absence of a clear
source of nociception in other chronic pain syndromes with no
evident structural lesions.69
Another chronic pain syndrome that affects a large proportion
of the population is chronic headaches. Few studies have
investigated ICI and ICF in patients having chronic migraines.
The findings were comparable with those for MPS and
fibromyalgia; patients had a reduced CSP13,28 or an increase in
ICF,60 suggesting that patients with chronic headaches have
a reduction of inhibitory circuits.
Although most studies on neuropathic pain confirmed these
findings, some trials on fibromyalgia and migraine found mixed
results. For instance, in fibromyalgia, pain reduction after trans-
cranial direct current stimulation has been found to be linked to
a reduction, not an increase, in ICI.1 In line with this observation,
Mhalla et al (2010) found that patients with fibromyalgia
demonstrate both reduced in ICF and ICI as compared to healthy
controls.39 Similar inconsistencies and opposite results have
been found in migraine.11 Therefore, we cannot generalize our
findings to all chronic pain syndromes for which some incon-
sistencies have been observed.
Beside chronic pain syndromes’ etiology, an important factor
to take into account is confounding because patients with chronic
pain generally have other symptoms such as depression, anxiety,
or fatigue.7,41,45 As exposed in 2 studies assessing the effect of
pain catastrophizing and anxiety on cortical excitability parame-
ters,65,66 these factors were also directly correlated to intra-
cortical disinhibition parameters. In fibromyalgia as well, fatigue,
catastrophizing, and depression correlated with higher dysregu-
lation of intracervical inhibition parameters.38 Therefore, cortical
disinhibition may not be directly related to chronic pain, but the
consequence of multiple factors related to this multifaceted
condition. Further data may provide the required level of detail to
understand potential differences and implications of disinhibition.
6. Conclusion
In this systematic review, we identified 4 studies investigating
intracortical disinhibition by means of corticospinal excitability (ICI
and ICF) in patients with MPS.3,8,65,66 Although this is a limited
amount of data, all 4 studies reported a decreased ICI and/or an
increased ICF, —supporting the intracortical disinhibition theory
in this population of patients. In addition, these trials highlighted
the association between other common psychological factors in
patients with chronic pain,62 such as pain catastrophizing or
anxiety and intracortical disinhibition measurements, further
demonstrating the importance of these neurophysiological
factors in chronic pain and related psychological symptoms.
The low number of studies we found regarding this matter
emphasizes the lack of neurophysiological markers for patients
with MPS. However, intracortical disinhibition measurements
have been identified in a reproducible way in different population
of patients having a chronic pain condition, more specifically in
neuropathic pain syndromes.57
Although the present data are too preliminary to draw
generalizable conclusions, they do support the intracortical
disinhibition theory in MPS, although not exclusively for this
specific condition. Further prospective trials exploring the re-
lationship between these neurophysiological measurements and
the development of chronic pain could shed light on the
development of neuroplastic changes in chronic pain syndromes.
In addition, larger trials assessing these markers in different
populations of patients having chronic pain could help to
differentiate and better characterize chronic pain diseases, as
well as finding similar aspects. A better understanding of
neurophysiological modifications related to chronic pain will give
new insights in the development of treatments targeting these
maladaptive changes, such as NIBS techniques (eg, rTMS and
transcranial direct current stimulation). Finally, intracortical
6 A. Thibaut et al.·2 (2017) e594 PAIN Reports®
disinhibition measurements could be used as an objective
measure of treatment efficacy, as compared to clinical scales,
and a potential predictive marker of a response to a treatment.
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